JAMA:美国近十年阿片类药物使用情况分析——借鉴意义重大

2015-10-14 zhaozhou 译 MedSci原创

自从1999年以来,由于处方类阿片镇痛药的非医疗用途的使用导致的死亡率和发病率在美国呈现逐年上升的趋势。在这段时间内,由于这些镇痛药的不当使用导致的急诊室人数上升和药物过量使用导致的死亡不断的上升。 据估计,由于阿片类镇痛药的使用导致的急诊就诊人数从2004年的每十万人中有82.5上升至每十万人中有184.1人。由此可见,处方阿片类镇痛药的滥用已经成为美国医疗卫生的一大问题。 

自从1999年以来,由于处方类阿片镇痛药的非医疗用途的使用导致的死亡率和发病率在美国呈现逐年上升的趋势。在这段时间内,由于这些镇痛药的不当使用导致的急诊室人数上升和药物过量使用导致的死亡不断的上升。 据估计,由于阿片类镇痛药的使用导致的急诊就诊人数从2004年的每十万人中有82.5上升至每十万人中有184.1人。由此可见,处方阿片类镇痛药的滥用已经成为美国医疗卫生的一大问题。
 

为了全面了解当前的阿片类药物滥用的流行病学状态,研究人员分析了两个国家数据库,以研究滥用的趋势、非医用处方阿片类药物的滥用障碍、使用频率以及由于此类药物滥用导致的死亡。由于药物使用的主要人群集中在青年和中年,因此研究对象主要是18-64岁的成年人。此项研究共搜集了472200名成年人的数据,这些人均参与了2003-2013国家药物使用与卫生调查。相关的死亡率的数据主要来自于2003-2013年国家重要数据系统。在这些成年人中,处方阿片类药物的非医用的流行率从2003年的5.4%下降至2013年的4.9%。但是,处方阿片类药物的使用障碍则从2003年的0.6%上升至2013年的0.9%。药物的12个月内高频率使用比例也出现了上涨。药物滥用致死也从2003年的每十万人中4.5例死亡上升至2013年的7.8例。
 
此项研究分析了数十万人的数据,说明阿片类药物的合理使用意义重大。这不仅对于美国,对于中国来说,也有相当大的借鉴意义。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=176424, encodeId=3e491e64245a, content=是吗?这些研究靠谱吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Feb 16 10:15:44 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971528, encodeId=d40c19e1528c9, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Dec 23 02:57:00 CST 2015, time=2015-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660810, encodeId=d7d81660810e0, content=<a href='/topic/show?id=17b8268041b' target=_blank style='color:#2F92EE;'>#使用情况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26804, encryptionId=17b8268041b, topicName=使用情况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=169625169742, createdName=dzx0922897, createdTime=Sat May 14 17:57:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252994, encodeId=19e312529940e, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Thu Oct 15 23:57:00 CST 2015, time=2015-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309005, encodeId=233d130900577, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu Oct 15 23:57:00 CST 2015, time=2015-10-15, status=1, ipAttribution=)]
    2017-02-16 虈亣靌

    是吗?这些研究靠谱吗

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=176424, encodeId=3e491e64245a, content=是吗?这些研究靠谱吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Feb 16 10:15:44 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971528, encodeId=d40c19e1528c9, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Dec 23 02:57:00 CST 2015, time=2015-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660810, encodeId=d7d81660810e0, content=<a href='/topic/show?id=17b8268041b' target=_blank style='color:#2F92EE;'>#使用情况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26804, encryptionId=17b8268041b, topicName=使用情况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=169625169742, createdName=dzx0922897, createdTime=Sat May 14 17:57:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252994, encodeId=19e312529940e, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Thu Oct 15 23:57:00 CST 2015, time=2015-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309005, encodeId=233d130900577, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu Oct 15 23:57:00 CST 2015, time=2015-10-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=176424, encodeId=3e491e64245a, content=是吗?这些研究靠谱吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Feb 16 10:15:44 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971528, encodeId=d40c19e1528c9, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Dec 23 02:57:00 CST 2015, time=2015-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660810, encodeId=d7d81660810e0, content=<a href='/topic/show?id=17b8268041b' target=_blank style='color:#2F92EE;'>#使用情况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26804, encryptionId=17b8268041b, topicName=使用情况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=169625169742, createdName=dzx0922897, createdTime=Sat May 14 17:57:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252994, encodeId=19e312529940e, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Thu Oct 15 23:57:00 CST 2015, time=2015-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309005, encodeId=233d130900577, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu Oct 15 23:57:00 CST 2015, time=2015-10-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=176424, encodeId=3e491e64245a, content=是吗?这些研究靠谱吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Feb 16 10:15:44 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971528, encodeId=d40c19e1528c9, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Dec 23 02:57:00 CST 2015, time=2015-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660810, encodeId=d7d81660810e0, content=<a href='/topic/show?id=17b8268041b' target=_blank style='color:#2F92EE;'>#使用情况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26804, encryptionId=17b8268041b, topicName=使用情况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=169625169742, createdName=dzx0922897, createdTime=Sat May 14 17:57:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252994, encodeId=19e312529940e, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Thu Oct 15 23:57:00 CST 2015, time=2015-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309005, encodeId=233d130900577, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu Oct 15 23:57:00 CST 2015, time=2015-10-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=176424, encodeId=3e491e64245a, content=是吗?这些研究靠谱吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Feb 16 10:15:44 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971528, encodeId=d40c19e1528c9, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Wed Dec 23 02:57:00 CST 2015, time=2015-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660810, encodeId=d7d81660810e0, content=<a href='/topic/show?id=17b8268041b' target=_blank style='color:#2F92EE;'>#使用情况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26804, encryptionId=17b8268041b, topicName=使用情况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=169625169742, createdName=dzx0922897, createdTime=Sat May 14 17:57:00 CST 2016, time=2016-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252994, encodeId=19e312529940e, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Thu Oct 15 23:57:00 CST 2015, time=2015-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309005, encodeId=233d130900577, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu Oct 15 23:57:00 CST 2015, time=2015-10-15, status=1, ipAttribution=)]
    2015-10-15 lhlxtx

相关资讯

JAMA Intern Med:防止阿片类药物滥用的新策略

美国佛罗里达州一直致力于减少处方阿片类药物的滥用和处方分配问题,一项发表于JAMA Internal Medicine中的最新研究显示,通过处方药物管理办法(PDMPs)和“药物滥用”法使得阿片类药物处方的开具和使用有了一定的缓解。“PDMPs和药物滥用法为解决处方药物滥用的流行趋势提供了有效地解决方法”,来自霍普金斯大学彭博公共卫生学院的首席科学家兰尼·卢特考如是说。&nbs

NEJM:全球阿片类药物滥用趋势分析报告

【1月26日讯】一项监测2002年—2013年间阿片类药物滥用趋势的研究显示,阿片类止痛药处方、阿片类转移和滥用以及阿片类相关死亡在2002年—2010年呈上升趋势。 然而,在2001年—2013年间上述三项测量指标呈平稳或下降的趋势。 “这表明美国对阿片类药物滥用作出了努力,而且干预措施确实见效了。”科罗拉多州丹佛卫生署及医院管理局药品中心主任、本研究的主要作者理查德·达特博士向

Lancet Psychiatry:阿片类药物治疗慢性非癌性疼痛研究

比较了WHO的ICD-10和建议的ICD-11以及美国精神病学协会的DSM-IV和DSM-5对澳大利亚以社区为基础的慢性非癌性疼痛的样本进行分类。 方法 我们研究了疼痛和阿片类药物治疗(POINT)的群组参与者,一项在澳大利亚各地社区药店在2012-2013年招募的1514人的为期2年前瞻性群组研究。对患者进行他们使用阿片类药物的综合性国际诊断访谈后,我们评估了那些阿片类药物使用障碍的患者通过I

PAIN:如何在大量EHR中发现opioid的使用问题?

在美国,阿片类镇痛药的处方量在1999-2011年间增长了两倍。尽管阿片类镇痛药在疼痛的规范治疗中发挥重要作用,但它在临床上的使用受到包括成瘾性和过量致死性在内的严重不良反应的限制。随着阿片类药物处方量的增加,1999-2010年间阿片类药物相关的死亡率增长了三倍以上,并且2004-2011年间与阿片类药物相关的意外事件发生率增长了两倍以上。对长期给予阿片类处方药来治疗慢性痛的病人,理解阿片类药物

Lancet Psychiatry:阿片类药物替代疗法(美沙酮vs丁丙诺啡)的死亡风险比较

阿片类药物依赖性增加了过早死亡的风险。使用美沙酮或丁丙诺啡替代阿片类药物治疗可降低死亡风险,尤其是对与药物过量有关的死亡。临床指南推荐美沙酮作为阿片类药物替代治疗的一线药物。该研究的目的是测试丁丙诺啡治疗是否比美沙酮治疗具有较低的死亡风险,通过比较在治疗诱导时,治疗过程药物的转换和治疗后停止用药的全因死亡率进行分析。研究人员在澳大利亚新南威尔士州做了一项所有具有阿片类药物依赖性患者的回顾性队列研究

一周研究进展荟萃:让你知识满满!

通宵工作 癌细胞 β受体阻滞剂 睡眠 阿片类药物 心衰 动脉硬化